| Model Name | Description |
| NCI-H1650 | Derived from human non-small cell lung cancer (NSCLC) with EGFR mutation, used to study targeted therapies and drug resistance. |
| PC9 | A human NSCLC model with EGFR exon 19 deletion, used to evaluate EGFR-targeted inhibitors. |
| Calu-1 | Derived from human lung epidermoid carcinoma, used to study aggressive NSCLC and chemotherapy response. |
| A427 | A human lung adenocarcinoma model used to assess tumor growth and therapeutic efficacy. |
| NCI-H647 | Derived from human large cell lung carcinoma, used to evaluate targeted lung cancer treatments. |
| NCI-H292 | A human lung mucoepidermoid carcinoma model used to study tumor progression and drug response. |
| NCI-H322 | Derived from human lung adenocarcinoma, used for studying NSCLC biology and treatment. |
| NCI-H358 | A human bronchioalveolar carcinoma model used to evaluate lung cancer therapies. |
| NCI-H441 | Derived from human lung adenocarcinoma, used to study tumor growth and therapeutic responses. |
| NCI-H520 | A human squamous cell lung carcinoma model used to study NSCLC and test treatments. |
| NCI-H2228 | Derived from human NSCLC with EML4-ALK fusion, used to evaluate ALK-targeted therapies. |
| SK-MES-1 | A human squamous cell lung carcinoma model used for testing anticancer agents. |
| NCI-H1299 | Derived from human NSCLC lacking p53, used to study tumor progression and drug resistance. |
| HCC4006 | A human lung adenocarcinoma model with EGFR mutation, used to evaluate targeted therapies. |
| NCI-H727 | Derived from human lung carcinoid tumor, used to study neuroendocrine lung cancers. |
| NCI-H2122 | A human NSCLC model used for investigating tumor growth and treatment efficacy. |
| DV-90 | Derived from human NSCLC, used to study tumor progression and drug response. |
| NCI-H69 | A human small cell lung cancer (SCLC) model used to study aggressive lung tumors and chemotherapy. |
| NCI-H1417 | Derived from human SCLC, used to evaluate novel therapies for aggressive lung cancer. |
| NCI-H446 | A human SCLC model used to study tumor biology and test anticancer treatments. |
| NCI-H526 | Derived from human SCLC, used for preclinical studies of small cell lung tumors. |
| NCI-H82 | A human SCLC model used to investigate tumor growth and therapeutic responses. |
| SHP-77 | Derived from human small cell lung carcinoma (SCLC); exhibits neuroendocrine features and is used for studying platinum-based chemotherapy response. |
| NCI-H2170 | Squamous cell carcinoma of the lung (NSCLC); EGFR wild-type, KRAS wild-type, used to evaluate therapies for squamous histology. |
| NCI-H820 | Lung adenocarcinoma harboring EGFR L858R and T790M mutations with MET amplification; used for EGFR and MET inhibitor studies. |
| NCI-H23 | KRAS-mutant (G12C) lung adenocarcinoma; p53-mutant, EGFR wild-type; a standard model for testing KRAS-targeted drugs. |
| NCI-H1568 | NSCLC adenocarcinoma; KRAS G12V mutant, STK11 wild-type, EGFR wild-type; used in studies of KRAS-driven tumor biology. |
| NCI-H1944 | Lung adenocarcinoma; KRAS mutant, EGFR wild-type, p53 mutant; commonly used in chemo- and immunotherapy evaluations. |
| NCI-H2023 | Lung adenocarcinoma; EGFR and KRAS wild-type; exhibits epithelial morphology, used in general NSCLC drug testing. |
| NCI-H2030 | KRAS G12C mutant, EGFR wild-type lung adenocarcinoma; used for developing and testing KRAS-G12C inhibitors. |
| NCI-H2126 | KRAS G12C and p53 mutant NSCLC; used to evaluate KRAS-targeted agents and pathway inhibition strategies. |
| NCI-H838 | Adenocarcinoma of the lung; KRAS mutant, EGFR wild-type, p53 wild-type; moderately differentiated tumor model. |
| NCI-H1838 | NSCLC with EGFR and KRAS wild-type genotype; used in testing broad-spectrum NSCLC therapeutics. |
| DMS114 | SCLC line with low neuroendocrine marker expression; RB1 wild-type, used to model non-classical small cell lung cancer. |
| NCI-H211 | Classic SCLC; p53 and RB1 mutant, high neuroendocrine marker expression; aggressive phenotype for chemo testing. |
| NCI-H209 | Small cell lung carcinoma; neuroendocrine subtype with classic SCLC mutations (p53, RB1 loss); used for platinum drug testing. |
| NCI-H2286 | NSCLC adenocarcinoma; KRAS G12A mutation; useful for evaluating KRAS-driven tumor response to targeted drugs. |
| NCI-H596 | Lung squamous cell carcinoma; PTEN-null, PIK3CA mutant; used to test PI3K/AKT/mTOR pathway inhibitors. |
| HCC44 | Lung adenocarcinoma harboring KRAS G12C mutation; EGFR wild-type; ideal for KRAS inhibitor testing. |
| NCI-H1373 | NSCLC with MET exon 14 skipping mutation and KRAS mutation; used for MET-targeted therapy evaluation. |
| SW1573 | NSCLC squamous cell carcinoma; KRAS G12C mutant, EGFR wild-type; responsive to MEK and KRAS pathway inhibitors. |
| LCLC-97TM1 | Large cell lung carcinoma; KRAS wild-type, EGFR wild-type; used in broad NSCLC drug efficacy studies. |
| HCC1588 | Squamous NSCLC model with unknown major driver mutations; used in general cytotoxic and radiation therapy research. |
| NCI-H1048 | SCLC with high neuroendocrine expression; MYC amplified; used for studying MYC-targeted therapies in SCLC. |
| NCI-H1581 | NSCLC with FGFR1 amplification; EGFR and KRAS wild-type; used to evaluate FGFR inhibitors. |
| NCI-H1781 | NSCLC adenocarcinoma with ERBB2 (HER2) exon 20 insertion mutation; used in HER2-targeted drug studies. |
| NCI-H1963 | NSCLC adenocarcinoma with MET amplification; EGFR/KRAS wild-type; ideal for MET inhibitor testing. |
| COLO699 | NSCLC adenocarcinoma; exhibits epithelial morphology; limited molecular data, used in broad efficacy testing. |
| NCI-H2135 | Lung adenocarcinoma; EGFR and KRAS wild-type; used for non-specific NSCLC drug studies. |
| EBC-1 | NSCLC with high-level MET amplification; used as a gold standard model for MET-targeted drug development. |
| NCI-H2172 | NSCLC adenocarcinoma; EGFR and KRAS wild-type; general use in cytotoxic and targeted agent screening. |
| LU99 | Lung adenocarcinoma with unknown driver status; used in broad-spectrum NSCLC drug testing panels. |
| DMS53 | SCLC model with moderate neuroendocrine features; used to study microtubule inhibitors and DNA-damaging agents. |
| NCI-H1355 | Adenocarcinoma of the lung; KRAS G13D mutation; EGFR wild-type; used to explore non-G12 KRAS mutation therapies. |
| NCI-H1395 | Lung adenocarcinoma; TP53 and STK11 mutant; microsatellite instability-high (MSI-H), rare in lung cancer. |
| NCI-H650 | SCLC model with high neuroendocrine differentiation; used to evaluate platinum-doublet chemotherapies. |
| SW900 | Squamous NSCLC; TP53 mutant, EGFR/KRAS wild-type; used in squamous-specific drug screens. |
| NCI-H2110 | NSCLC adenocarcinoma; ALK and ROS1 negative, EGFR/KRAS wild-type; used in standard chemotherapy testing. |
| NCI-H146 | Classic SCLC with p53 and RB1 loss; neuroendocrine phenotype; sensitive to etoposide/cisplatin combinations. |
| NCI-H1623 | NSCLC adenocarcinoma; KRAS G12C mutant; useful for KRAS inhibitor and downstream pathway blockade studies. |
| NCI-H1770 | NSCLC adenocarcinoma; ALK, EGFR, KRAS wild-type; used to screen therapies with unknown drivers. |
| NCI-H2347 | NSCLC adenocarcinoma with RB1 wild-type and STK11 loss; used to study immunotherapy resistance mechanisms. |